间充质干细胞在肿瘤治疗应用的研究进展

Abstract
Figure/Table
References (41)
Related Citation (10)

Download: PDF (480 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract As a kind of pluripotent stem cells,mesenchymal stem cells (MSCs) have a wide range of biological functions.In the treatment of intracerebral tumors,the existence of blood brain barrier (BBB) hinders the diffusion of drugs to intracranial tumors,and drugs are difficult to achieve effective treatment.MSCs can bypass the BBB,so they can be used as drug carriers in the treatment of intracranial tumors.The genetically modified MSCs can migrate to the local tumor and play a therapeutic role,significantly reducing the toxic side effects on normal cells.Based on the existing studies,MSCs have a broad prospect in the application of tumor treatment.This paper reviews the interaction between MSCs and tumor cells,the effect of MSCs on the tumor microenvironment,the application of MSCs as drug carrier in tumor treatment,the genetically modified MSCs in tumor treatment,and the extracellular vesicles(EVs)secreted by MSCs in tumor treatment and other aspects of research progress.

Key words： Mesenchymal stem cell Tumor treatment Tumor microenvironment Exosomes

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	HUANG Zhongkai
	XU Yechi
	XU Shouyu
	ZHU Rusen

Cite this article:

HUANG Zhongkai,XU Yechi,XU Shouyu, et al. Research progress on mesenchymal stem cells in tumor treatment[J]. 中国当代医药, 2022, 29(14): 27-31.

URL:

https://www.dangdaiyiyao.com/EN/ OR https://www.dangdaiyiyao.com/EN/Y2022/V29/I14/27

[26]	Wong S，Kong W，Fang C，et al.The TRAIL to cancer therapy：Hindrances and potential solutions[J].Crit Rev Oncol Hematol，2019，143：81-94.
[31]	Schey KL，Luther JM，Rose KL.Proteomics characterization of exosome cargo[J].Methods，2015，87：75-82.
[1]	Ostrom Q，Gittleman H，Liao P，et al.CBTRUS Statistical Report：Primary brain and other central nervous system tumors diagnosed in the United States in 2010-2014[J].Neuro Oncol，2017，19（suppl 5）：v1-v88.
[2]	Melzer C，Jacobs R，Dittmar T，et al.Reversible Growth-Arrest of a Spontaneously-Derived Human MSC-Like Cell Line[J].Int J Mol Sci，2020，21（13）：4752.
[3]	Mishra P，Mishra P，Humeniuk R，et al.Carcinoma-associated fibroblast -like differentiation of human mesenchymal stem cells[J].Cancer Res，2008，68（11）：4331-4339.
[4]	Spaeth E，Dembinski J，Sasser A，et al.Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression[J].PloS one，2009，4（4）：e4992.
[5]	Fridman W，Pagès F，Sautès-Fridman C，et al.The immune contexture in human tumours：impact on clinical outcome[J].Nat Rev Cancer，2012，12（4）：298-306.
[6]	Suzuki K，Sun R，Origuchi M，et al.Mesenchymal stromal cells promote tumor growth through the enhancement of neovascularization[J].Mol Med，2011，17（7-8）：579-587.
[7]	Djouad F，Bony C，Apparailly F，et al.Earlier onset of syngeneic tumors in the presence of mesenchymal stem cells[J].Transplantation，2006，82（8）：1060-1066.
[23]	Srinivasan V，Gumin J，Camstra K，et al.Microcatheter delivery of neurotherapeutics：compatibility with mesenchymal stem cells[J].J Neurosurg，2019，1-9.
[24]	Marofi F，Vahedi G，Biglari A，et al.Mesenchymal Stromal/Stem Cells：A New Era in the Cell-Based Targeted Gene Therapy of Cancer[J].Front Immunol，2017，8：1770.
[25]	Zhang J，Kale V，Chen M.Gene-directed enzyme prodrug therapy[J].AAPS J，2015，17（1）：102-110.
[8]	Sasser AK，Sullivan NJ，Studebaker AW，et al.Interleukin-6 is a potent growth factor for ER-alpha-positive human breast cancer[J].FASEB J，2007，21（13）：3763-3770.
[9]	Rowan BG，Gimble JM，Sheng M，et al.Human adipose tissuederived stromal/stem cells promote migration and early metastasis of triple negative breast cancer xenografts[J].PLoS One，2014，9（2）：e89595.
[10]	Christodoulou I，Goulielmaki M，Devetzi M，et al.Mesenchymal stem cells in preclinical cancer cytotherapy：a systematic review[J].Stem Cell Res Ther，2018，9（1）：336.
[11]	Wiedswang G，Borgen E，Karesen R，et al.Detection of isolated tumor cells in bone marrow is an independent prognostic factor in breast cancer[J].J Clin Oncol，2003，21（18）：3469-3478.
[12]	Rhodes L，Muir S，Elliott S，et al.Adult human mesenchymal stem cells enhance breast tumorigenesis and promote hormone independence[J].Breast Cancer Res Treat，2010，121（2）：293-300.
[13]	Ren G，Zhao X，Wang Y，et al.CCR2-dependent recruitment of macrophages by tumor-educated mesenchymal stromal cells promotes tumor development and is mimicked by TNFα[J].Cell Stem Cell，2012，11（6）：812-824.
[14]	Nishimura K，Semba S，Aoyagi K，et al.Mesenchymal stem cells provide an advantageous tumor microenvironment for the restoration of cancer stem cells[J].Pathobiology，2012，79（6）：290-306.
[15]	Martin F，Dwyer R，Kelly J，et al.Potential role of mesenchymal stem cells（MSCs）in the breast tumour microenvironment：stimulation of epithelial to mesenchymal transition （EMT）[J].Breast Cancer Res Treat，2010，124（2）：317-326.
[16]	Karnoub A，Dash A，Vo A，et al.Mesenchymal stem cells within tumour stroma promote breast cancer metastasis[J].Nature，2007，449（7162）：557-563.
[17]	Ikeda T，Nishita M，Hoshi K，et al.Mesenchymal stem cellderived CXCL16 promotes progression of gastric cancer cells by STAT3-mediated expression of Ror1[J].Cancer Sci，2020，111（4）：1254-1265.
[18]	Tabe Y，Konopleva M，Munsell MF，et al.PML-RARalpha is associated with leptin-receptor induction：the role of mesenchymal stem cell-derived adipocytes in APL cell survival[J].Blood，2004，103（5）：1815-1822.
[19]	Norozi F，Ahmadzadeh A，Shahrabi S，et al.Mesenchymal stem cells as a double-edged sword in suppression or progression of solid tumor cells[J].Tumour Biol，2016，37（9）：11679-11689.
[20]	Mager L，Burkhard R，Pett N，et al.Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy[J].Science，2020，369（6510）：1481-1489.
[21]	Matson V，Fessler J，Bao R，et al.The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients[J].Science，2018，359（6371）：104-108.
[22]	Riquelme E，Zhang Y，Zhang L，et al.Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes[J].Cell，2019，178（4）：795-806.e12.
[27]	Golinelli G，Grisendi G，Prapa M，et al.Targeting GD2-positive glioblastoma by chimeric antigen receptor empowered mesenchymal progenitors[J].Cancer Gene Ther，2020，27：558-570.
[28]	Yuan Z，Kolluri K，Sage E，et al.Mesenchymal stromal cell delivery of full-length tumor necrosis factor-related apoptosis-inducing ligand is superior to soluble type for cancer therapy[J].Cytotherapy，2015，17（7）：885-896.
[29]	Yang Z，Tang X，Guo X，et al.Cancer cell-oriented migration of mesenchymal stem cells engineered with an anticancer gene（PTEN）：an imaging demonstration[J].Onco Targets Ther，2014，7：441-446.
[30]	Guo X，Hu Q，Yuan Y，et al.PTEN -mRNA engineered mesenchymal stem cell -mediated cytotoxic effects on U251 glioma cells[J].Oncol Lett，2016，11（4）：2733-2740.
[32]	Bernardi S，Zanaglio C，Farina M，eet al.dsDNA from extracellular vesicles（EVs）in adult AML[J].Ann Hematol，2021，100（5）：1355-1356.
[33]	Castellani C，Burrello J，Fedrigo M，et al.Circulating extracellular vesicles as non-invasive biomarker of rejection in heart transplant[J].J Heart Lung Transplant，2020，39（10）：1136-1148.
[35]	Ha D，Yang N，Nadithe V.Exosomes as therapeutic drug carriers and delivery vehicles across biological membranes：current perspectives and future challenges[J].Acta Pharm Sin B，2016，6（4）：287-296.
[36]	Shigemoto-Kuroda T，Oh J，Kim D，et al.MSC-derived Extracellular Vesicles Attenuate Immune Responses in Two Autoimmune Murine Models：Type 1 Diabetes and Uveoretinitis[J].Stem cell reports，2017，8（5）：1214-1225.
[37]	Mendt M，Kamerkar S，Sugimoto H，et al.Generation and testing of clinical-grade exosomes for pancreatic cancer[J].JCI Insight，2018，3（8）：e99263.
[38]	Mentkowski KI，Lang JK.Exosomes Engineered to Express a Cardiomyocyte Binding Peptide Demonstrate Improved Cardiac Retention in Vivo[J].Sci Rep，2019，9（1）：10041.
[39]	Dai S，Wei D，Wu Z，et al.Phase I clinical trial of autologous ascites-derived exosomes combined with GM-CSF for colorectal cancer[J].Mol Ther，2008，16（4）：782-790.
[34]	Rikkert LG，Beekman P，Caro J，et al.Cancer-ID：Toward Identification of Cancer by Tumor-Derived Extracellular Vesicles in Blood[J].Front Oncol，2020，10：608.
[40]	Wolfers J，Lozier A，Raposo G，et al.Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming[J].Nat Med，2001，7（3）：297-303.
[41]	Zitvogel L，Regnault A，Lozier A，et al.Eradication of established murine tumors using a novel cell-free vaccine：dendritic cell-derived exosomes[J].Nat Med，1998，4（5）：594-600.